NeuroMetrix Reports Scientific Presentation at the PAINWeek 2020 Live Virtual Conference
September 04 2020 - 7:00AM
NeuroMetrix, Inc. (Nasdaq: NURO) today reported that it will
present a scientific poster at the PAINWeek 2020 Live Virtual
Conference to be held September 11 - 13. PAINWeek is the
preferred resource in the U.S. for frontline practitioners treating
acute and chronic pain.
The poster is titled "Real-World Outcomes from High-Dose
Transcutaneous Electrical Nerve Stimulation in Individuals With
Chronic Knee Pain". The poster presents an analysis of 1,136
Quell® users with chronic knee pain who used their device regularly
over the first 70 days following initiation of therapy. A key
strength of this longitudinal observational study was the use of an
intention-to-treat analysis to decrease bias. The study
demonstrated a clinically meaningful group mean improvement in pain
severity and functional impairment as assessed by the Brief Pain
Inventory - Short Form.
About Quell
Quell is a novel transcutaneous electrical nerve stimulator
(TENS) for the symptomatic relief and management of chronic pain
that is available over-the-counter. It is a wearable device that
can be used during the day while active and at night while
sleeping. Quell users can personalize and manage therapy discreetly
via the Quell app. Quell also offers health tracking metrics
relevant to chronic pain sufferers. Quell users can synchronize
their data with the Quell Health Cloud®, which provides customized
feedback and powers a large chronic pain outcomes database. Visit
QuellRelief.com for more information.
About NeuroMetrix
NeuroMetrix is a leading developer and manufacturer of
diagnostic and therapeutic neurostimulation-based medical devices
that are used throughout the world. The Company has three FDA
cleared commercial products. DPNCheck® is a point-of-care test that
is used to evaluate peripheral neuropathies. ADVANCE™ is a
point-of-care device that provides nerve conduction studies as an
aid in diagnosing and evaluating patients suspected of having focal
or systemic neuropathies. Quell® is a wearable, mobile app enabled,
neurostimulation device indicated for symptomatic relief and
management of chronic pain and is available over-the-counter. The
Company maintains an active, industry-leading R&D program. For
more information, visit NeuroMetrix.com.
NeuroMetrix, Inc. Thomas T. Higgins, 781-314-2761 SVP and Chief
Financial Officer neurometrix.ir@neurometrix.com
Source: NeuroMetrix, Inc.
NeuroMetrix (NASDAQ:NURO)
Historical Stock Chart
From Mar 2024 to Apr 2024
NeuroMetrix (NASDAQ:NURO)
Historical Stock Chart
From Apr 2023 to Apr 2024